Eltrombopag has a role in the treatment of immune thrombocytopenia, although the drug is not a first-line treatment. The first line of clinical treatment for immune thrombocytopenia is glucocorticoids and intravenous gammaglobulin, and the second line of treatment is the use of thrombopoietin immunosuppressants, such as vincristine, or splenectomy. If none of the above treatments are effective or ineffective, then Eltrombopag can be tried. Eltrombopag can promote the differentiation and proliferation of megakaryocytes, thus working to increase the platelet level in the blood, and can be used in patients who are not well treated with immunosuppressants, glucocorticoids, immunoglobulins, or splenectomy. Immune thrombocytopenia is recommended to be treated as early as possible under the guidance of a specialist, the above drugs should be used under the guidance of a physician, should avoid blind self-medication.